Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 2010-2014  (1,657)
  • Medicine  (1,657)
Type of Medium
Language
Years
  • 2010-2014  (1,657)
Year
  • 1
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 4425-4425
    Abstract: Abstract 4425 Introduction: Despite the major benefit of TKI in the treatment of Chronic Myeloid Leukemia (CML) chronic phase, some of patients are resistant or progress to blast phase (BP) becoming not very accessible to therapy. We have been interested in the Syk molecule as a potential marker for CML progression for several reasons: i) its potential interaction with Src kinases, activated by BCR-ABL, and tyrosine kinase receptors, ii) its involvement in the molecular complexes activating actin and the cytoskeleton and integrin signalling pathways, regulating cell adhesion, a property that is impaired in CML, iii) its interaction with the PI3K/Akt pathway, activated by BCR-ABL. Furthermore, resistance to nilotinib was recently showed dependent on Syk expression. Method: The amount of Syk transcript was analyzed in primary cells using the 2-ΔΔ Ct method and was normalized to the endogenous reference gene (β2-microglobuline) and K562 cells as the calibrator. Using flow cytometry, we evaluated the expression of Syk and pSyk348 in K562 cells and in polymorphonuclear cells from 3 healthy donors (HD-PMN), primitive CML cells from 15 patients in chronic phase (CP) (patients #1 to #15) at diagnosis, in the blast cells from 4 patients in accelerated phase (AP) (patient#16, #17, #18 and #19) and from 2 patients in blast crisis (BC) (patient#20, #21). The level of intracellular dasatinib (DAS) was evaluated by an original flow cytometry method (Bourgne et al. Cytometry Part A, in press). Results: We observed a significant over expression of Syk mRNA in BP-CML cells, whereas there is no difference between HD-PMN and CP-CML cells. At the protein level we detected a decrease (2 times; p 〈 0.001) in and a tendency to increase (1.5 times; p=0.5) in the expression of Syk in CP-CML cells and BP-CML cells respectively compared with HD-PMN cells. Interestingly, we did not observe any expression of pSyk348 in HD-PMN or in granulocytic cells from CP-CML (n=15) but we systematically detected pSyk348 expression in the blast cells of the 6 patients (positive/control ratio: 2.3 ± 0.3) in advanced phases of CML. Moreover we did not found Syk phosphorylation in CP cells from one patient resistant to imatinib, then nilotinib and dasatinib but we detected pSyk348 only when his CML progressed, strengthening the hypothesis of a link between Syk phosphorylation and BP of CML. We confirmed in vitro that Dasatinib was able to rapidly (15 min) inhibit Syk phosphorylation in K562 cells and in blast cells from patient #17. Then we could follow dasatinib uptake into target blast cells, and expression of pSyk348 before and 6, 12, 36, 60, 84 and 136 hours after the first dose of DAS. We observed a significant storage of DAS in blast cells reaching a plateau after the 4th dose even though analyses were done 12 hrs after each dose. However, after a slight fall of blood leukocytes and blast cells numbers corresponding to a sharp drop of pSyk348 we observed an increase of blood malignant cells in parallel of a strong recurrence of pSyk348 at H60. Discussion: We observed a constitutive expression of Syk348 only in blast cells from advanced phases of CML, including in one patient we could follow from the TKI resistant phases to blast phase, strongly suggesting that Syk activation could be a pertinent biomarker for CML progression and could represent a potential target for combinatory therapy. The fact that we observed in one patient a correlation between Syk348 expression and malignant cell resistance even though cells stored dasatinib suggests a BCR-ABL/Src kinases independent mechanism of Syk phosphorylation in blast cells. Targeting Syk in BP-CML should offer new therapeutic option to patients with disease progression. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 124, No. 21 ( 2014-12-06), p. 4363-4363
    Abstract: Hematopoietic stem cell (HSC) function is critical in maintaining hematopoiesis continuously throughout the lifespan of an organism and any change in their ability to self-renew and/or to differentiate into blood cell lineages induces severe diseases. Postnatally, HSC are mainly located in bone marrow where their stem cell fate is regulated through a complex network of local influences, thought to be concentrated in the bone marrow (BM) niche. Despite more than 30 years of research, the precise location of the HSC niche in human BM remains unclear because most observations were obtained from mice models. BM harvesting collects macroscopic coherent tissue aggregates in a cell suspension variably diluted with blood. The qualitative interest of these tissue aggregates, termed hematons, was already reported (first by I. Blaszek's group (Blaszek et al., 1988, 1990) and by our group (Boiret et al., 2003)) yet they remain largely unknown. Should hematons really be seen as elementary BM units, they must accommodate hematopoietic niches and must be a complete ex vivo surrogate of BM tissue. In this study, we analyzed hematons as single tissue structures. Biological samples were collected from i) healthy donor bone marrow (n= 8); ii) either biological samples collected for routine analysis by selecting bone marrow with normal analysis results (n=5); or iii) from spongy bone collected from the femoral head during hip arthroplasty (n=4). After isolation of hematons, we worked at single level, we used immunohistochemistry techniques, scanning electronic microscopy, confocal microscopy, flow cytometry and cell culture. Each hematon constitutes a miniature BM structure organized in lobular form around the vascular tree. Hematons are organized structures, supported by a network of cells with numerous cytoplasmic expansions associated with an amorphous structure corresponding to the extracellular matrix. Most of the adipocytes are located on the periphery, and hematopoietic cells can be observed as retained within the mesenchymal network. Although there is a degree of inter-donor variability in the cellular contents of hematons (on average 73 +/- 10 x103 cells per hematon), we observed precursors of all cell lines in each structure. We detected a higher frequency of CD34+ cells than in filtered bone marrow, representing on average 3% and 1% respectively (p 〈 0.01). Also, each hematon contains CFU-GM, BFU-E, CFU-Mk and CFU-F cells. Mesenchymal cells are located mainly on the periphery and seem to participate in supporting the structure. The majority of mesenchymal cells isolated from hematons (21/24) sustain in vitro hematopoiesis. Interestingly, more than 90% of the hematons studied contained LTC-ICs. Furthermore, when studied using confocal microscopy, a co-localization of CD34+ cells with STRO1+ mesenchymal cells was frequently observed (75% under 10 µm of the nearest STRO-1+ cell, association statistically highly significant; p 〈 1.10-16). These results indicate the presence of one or several stem cell niches housing highly primitive progenitor cells. We are confirming these in vitro data with an in vivo xenotransplantation model. These structures represent the elementary functional units of adult hematopoietic tissue and are a particularly attractive model for studying homeostasis of the BM niche and the pathological changes occurring during disease. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of the American College of Cardiology, Elsevier BV, Vol. 60, No. 17 ( 2012-10), p. B156-
    Type of Medium: Online Resource
    ISSN: 0735-1097
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2012
    detail.hit.zdb_id: 1468327-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: American Heart Journal, Elsevier BV, Vol. 162, No. 1 ( 2011-07), p. 98-105.e1
    Type of Medium: Online Resource
    ISSN: 0002-8703
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2011
    detail.hit.zdb_id: 2003210-9
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 118, No. 21 ( 2011-11-18), p. 1102-1102
    Abstract: Abstract 1102 Introduction: Gaucher disease (GD) is due to an inborn deficiency of glucocerebrosidase (GC), that leads to the accumulation of glucosylceramide in monocytes/macrophages, known as “Gaucher cells”, which are thought to be responsible for a wide range of symptoms. Imiglucerase (CEREZYME®, Genzyme Corporation) (IMI) is the first line treatment of type 1 GD patients. Two new biosimilar agents, velaglucerase-alfa (VPRIV®, Shire Human Genetic Therapies, Dublin, Ireland) (VEL) and taliglucerase-alfa (PROTALIX®, Biotherapeutics, Pfizer) (TAL), have been described as being similar to IMI but differing slightly in glycan structure which could have an impact on macrophage uptake and thus on therapeutic efficacy. However, the ability of native GD cells to capture recombinant enzymes (REs) remains unknown. We used blood monocytes (Mo) from GD patients and healthy donors (HD) as a model to compare the uptake of the three REs. Patients and methods: After informed consent was obtained, cells were obtained from healthy donor blood (n=34). The left over part of biological samples collected for routine analysis from Gaucher patients (n=6) could be used for research because patients had been informed and did not verbally express any disagreement. Mononuclear cells were incubated with three concentrations of each RE (0.1, 0.5 and 1 U/ml) at 37°C for 30 minutes and one hour and washed twice with PBS to eliminate exogenous RE before evaluation of intra-cellular GC activity by standardized flow cytometry as previously described (Berger J. et al., Br J Haematol 2010) Results: Firstly, we confirmed that GD Mo (n=6) showed a marked enzyme deficiency (about 7% of the normal endogenous activity) as compared to normal glucocerebrosidase activity (GCA) (n=34) Then we observed a dose-dependent in vitro uptake of IMI, TAL and VEL in Mo from 4 untreated GD patients. However, the intra-monocyte (IMo) GCA of TAL was systematically lower than that of IMI and VEL. Case analysis showed an inter-patient heterogeneity, with the highest increase of intra-monocyte enzyme activity for all REs in patient #2 and the lowest in patient #3; this observation was confirmed in vivo by analysis of Mo 15 min. after the end of the first IMI infusion (× 38 and × 9 endogeneous IMoGCA respectively) whereas patient #2 had received a lower dose of enzyme (45 U/kg/2 weeks vs 60 U/kg/2 weeks). Interestingly, patient #2 showed mild GD suffering only thrombocytopenia and asthenia while patient #3 had an aggressive form of GD, with bone disorders (aseptic osteonecrosis, bone infarction and pseudarthrosis after traumatic fracture). Patient #2 responded rapidly, with improved thrombocytopenia (68%) and increased hemoglobin level (+1.9g/dL) from M3 but hematological response for patient #3 could not be evaluated because initial parameters had been normal in this patient who had been splenectomized 20 years ago. Because of the chitotriosidase deficiency of patient #2, we used plasma CCL18 as a biomarker; its kinetic of decrease was clearly more rapid than for patient #3. Similarly, correction of glycosylated-ferritin was better than in patient #2. The two other patients with IMoGCA values close to that of patient #2 had non-progressive disease not requiring treatment (patient #1), or had thrombocytopenia that improved over the expected period of time (patient #4). Discussion: In conclusion, this study shows inter-patient variability in the ability of blood Mo to store recombinant enzymes which to our knowledge has not been previously reported. This was confirmed in vivo 15 min. after the start of the infusion. This variability could partially explain the heterogeneity of GD response to enzyme replacement therapy. In this small series, the least aggressive disease corresponded to the highest intra-monocyte GCA and the most aggressive disease to the least intra-monocyte GCA. Six-month follow-up showed differences in change in biological biomarkers suggesting a relationship between intra-monocyte GCA and disease response. Furthermore in this in vitro GD Mo model, all the compounds available are not similar, even if their chemical structures are only slightly different with no relationship with the expression of the CD206 (data not shown). Another RE influx mechanism could exist and influence enzyme replacement therapy. These findings could help in customizing replacement therapy. Disclosures: Belmatoug: Genzyme: Consultancy; Shire: Research Funding. Berger:Shire: Consultancy; Genzyme: Consultancy, Research Funding.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2011
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2011
    In:  European Archives of Oto-Rhino-Laryngology Vol. 268, No. 2 ( 2011-2), p. 235-240
    In: European Archives of Oto-Rhino-Laryngology, Springer Science and Business Media LLC, Vol. 268, No. 2 ( 2011-2), p. 235-240
    Type of Medium: Online Resource
    ISSN: 0937-4477 , 1434-4726
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2011
    detail.hit.zdb_id: 1459042-6
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4352-4352
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4352-4352
    Abstract: Erufosine is a new antineoplastic agent from the class of alkylphosphocholines, which interferes with AKT phosphorylation, the related signal transduction and confers apoptosis. An improved understanding of its mode of action is important for its potential clinical application. The present study demonstrates that erufosine's antileukemic efficacy is related to the level of cellular retinoblastoma (Rb) protein expression. Stable Rb-knockdown in SKW-3 leukemia T-cells was induced by lentiviral delivery of constructs expressing short-hairpin-RNA species with 21 or 27 bp lengths. The cytotoxicity of erufosine was tested via MTT proliferation test on thus engineered cell populations with reduced Rb expression levels. Likewise, the clonogenicity of these engineered cell populations was determined by CFU assay before and after treatment with erufosine. The effects on cell cycle were investigated by FACS analysis. The expression of signal transduction factors was examined by RT-PCR and immunoblot. The Rb protein expression levels in the shRNA-transduced cells ranged from 1%- 36% of wild type or nonsense control. Low Rb expression correlated with significantly diminished antiproliferative and anticlonogenic activities of erufosine (p & lt;0.05) at concentrations near and above the IC50. Erufosine induced a G2 arrest, and complete Rb-deficiency aggravated this condition. With regard to proteins involved in cell cycle and apoptosis induction, Rb-deficiency reduced the expression of cyclin D3, that of the subsequently regulated kinase Cdk 4 and activated caspases 3 and 9, followed by PARP-cleavage. In partial variance, erufosine reduced cyclin D3 at RNA and protein levels, but affected not or only slightly the expression of its partner kinase Cdk 4. Rb-knockdown impaired the cytotoxic effect of erufosine significantly and contributed to the formation of a resistant cell fraction. It is concluded that Rb is a main mediator of erufosine's antileukemic activity and this suggests that the effect of the drug in patients might be predicted by determining the Rb expression status. Citation Format: Maya M. Zaharieva, Milen Kirilov, Minquang Chai, Stefan M. Berger, Spiro M. Konstantinov, Martin R. Berger. Down regulation of retinoblastoma protein expressionimpedes the antileukemic activity of erufosine. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4352. doi:10.1158/1538-7445.AM2013-4352
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2014
    In:  Cancer Research Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2614-2614
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2614-2614
    Abstract: Breast cancer is a leading cause of cancer related death in women due to onset of metastasis. Bone metastasis is the most frequent complication occurring in patients with advanced breast cancer and bone sialoprotein (BSP) is related to this process. However, the underlying mechanisms are not clear yet. Therefore, the aim of the study was to analyze BSP functions in greater detail and to decipher its signaling pathways contributing to bone metastasis. To that purpose a combination of the tetracycline-controlled transcription activation system (“Tet-Off system”) and RNA interference was used to initiate and maintain the conditional knockdown of BSP for any intended period. This new technique was established in MDA-MB-231 subclones by recombinase-mediated cassette exchange. Additionally, the cell clones were equipped with the reporter genes mCherry and firefly luciferase for testing their regulative properties and following their fate. In absence of doxycycline, the expression of a miRNA targeting BSP was activated and after six days of BSP knockdown the ensuing cellular, metastatic or molecular properties were monitored by fluorescent microscopy, flow cytometry analysis, assays for proliferation, migration and colony formation, as well as expression profiling analysis. Furthermore, the cell clones were examined in a nude rat model for soft tissue and osteolytic lesions after 2 to 6 weeks of miRNA treatment. The clones revealed good regulative properties to doxycycline. Phenotypic changes indicating apoptosis were observed after 6 days of conditional knockdown which was characterized by up to 86% decreased BSP levels and resulted in significant anti-proliferative, anti-migratory and anti-clonogenic effects in vitro. Additionally, the effect of miRNA-mediated BSP knockdown was assessed in vivo. Significant decreases (p & lt; 0.03) and even complete remissions of soft tissue and osteolytic lesions were found following 3 and 6 weeks of miRNA treatment by bioluminescence and magneting resonance imaging, as well as volume computed tomography. The microarray data showed modulated expression in 1.3% of all genes, thus hinting to specific effects in response to BSP knockdown. These genes included increased expression of endoplasmic reticulum stress and apoptosis related genes (ATF3, CHOP), of transcription factor c-FOS, of the gene related to breast epithelial differentiation (ID2) and the tumor suppressor gene EGR1. Conversely, there was suppression of metastasis associated genes (CD44, IL11). These findings were confirmed by western blot for induction of intrinsic and extrinsic apoptotic pathways as shown by cleavage of caspases 8, 9, 3 and 7, and of PARP, as well as the upregulation of ATF3, DDIT3 (CHOP), c-FOS, ID2 and CD44. In conclusion, the role of BSP in the development of skeletal metastasis has been defined more precisely and renders this protein an attractive target in the treatment of this disease. Citation Format: Marineta Kovacheva, Michael Zepp, Stefan Berger, Martin R. Berger. Bone sialoprotein is an essential target in breast cancer skeletal metastasis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2614. doi:10.1158/1538-7445.AM2014-2614
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    SAGE Publications ; 2013
    In:  The Cleft Palate-Craniofacial Journal Vol. 50, No. 5 ( 2013-09), p. 528-534
    In: The Cleft Palate-Craniofacial Journal, SAGE Publications, Vol. 50, No. 5 ( 2013-09), p. 528-534
    Abstract: To estimate the prevalence of platybasia in patients with velopharyngeal incompetence (VPI) and its relation with palatal anomalies and syndromes. Design and Settings Retrospective case analysis. Setting A university-affiliated hospital. Patients The VPI patients (n =366) included five groups with either cleft lip and palate (CLP), cleft palate (CP) only, submucous cleft palate (SMCP), occult submucous cleft palate (OSMCP), or non-CP. The control group (n = 126) comprised healthy, normal-speech individuals. Outcome Measures The cranial-base angle was measured by lateral cephalometric radiography. The prevalence of platybasia (defined as cranial base angle 〉 137°) was estimated and the patient's syndromes were recorded. Results The prevalence of platybasia was significantly higher in the VPI group (28.7%) than in the normal controls (2.4%) (P 〈 .001). A significant difference (P 〈 .01) was found in the prevalence of platybasia among the five VPI groups: 16.7%, 20.3%, 28.8%, 33.7%, and 40.3% for CLP, CP only, SMCP, OSMCP, and non-CP, respectively. No significant difference was found between the cranial-base angle of VPI patients and of controls and between the cranial-base angle of the five VPI groups. The VPI nonplatybasic patients had a significantly smaller cranial-base angle than normal controls (P 〈 .01). Platybasia was the highest among patients with velocardiofacial syndrome (50%), followed by those with Pierre Robin syndrome (27.3%). Conclusions Platybasia, which may cause enlargement of the nasopharyngeal space and difficulties in achieving velopharyngeal closure, can be found in high numbers of VPI patients with or without CP. This supports the belief that velopharyngeal anomaly may be part of a more complex craniofacial anomaly influenced by the cranial-base flexure.
    Type of Medium: Online Resource
    ISSN: 1055-6656 , 1545-1569
    RVK:
    Language: English
    Publisher: SAGE Publications
    Publication Date: 2013
    detail.hit.zdb_id: 2030056-6
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Online Resource
    Online Resource
    Elsevier BV ; 2010
    In:  Neuromuscular Disorders Vol. 20, No. 12 ( 2010-12), p. 826-832
    In: Neuromuscular Disorders, Elsevier BV, Vol. 20, No. 12 ( 2010-12), p. 826-832
    Type of Medium: Online Resource
    ISSN: 0960-8966
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2010
    detail.hit.zdb_id: 2008287-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages